B Acute Lymphoblastic Leukemia Clinical Trial
— LABMIOfficial title:
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
Verified date | September 2022 |
Source | University Hospital, Angers |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
B-acute lymphoblastic leukaemia (ALL) is the most common childhood malignancy. Despite enhancement of childhood B-ALL outcome, relapses remain difficult to treat. Several studies in adult acute myeloid leukaemia have shown that proliferation of immunosuppressive cells -particularly T regulatory (Treg) cells and deficient natural killer (NK) cells- was associated with poor response to chemotherapy. However, few studies have been done on childhood ALL and none on relapse of B-ALL. Moreover, a newly described immunosuppressive B cells subset (Breg cells) seems to have a role in oncogenesis in mice model, but its significance has never been evaluated in human cancers. The purpose of this study is to prospectively evaluate the immune status of children newly diagnosed with first relapse of B-cell ALL, and to compare results with those of children treated for B-ALL in complete remission. Classic lymphocytic phenotype, proportions of immunosuppressive cells (Treg cells, deficient NK cells, Cytotoxic T-lymphocyte-associated protein 4 and/or Programmed T cell death 1) and thymopoiesis will be evaluated. The investigators assume that increase of immunosuppressive cells proportions could be associated with B-ALL relapse.
Status | Terminated |
Enrollment | 119 |
Est. completion date | September 2022 |
Est. primary completion date | September 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 18 Years |
Eligibility | 1. Inclusion Criteria for relapse Group : - Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis - Obtention of oral and written consent of the parents - Parents affiliated with the social security system 2. Inclusion Criteria for control Group : - Children aged from 1 to 18 years enrolled into FRALLE or EORTC treatment protocols, treated for B-ALL and who are in complete molecular remission - Obtention of oral and written consent of the parents - Parents affiliated with the social security system 3. Exclusion criteria for control Group are the same as for relapsed Group : - Children with hematologic syndrome predisposing to hematologic neoplasia (such as Fanconi's anaemia, Diamond Blackfan anaemia …) or acute leukemia secondary to previous treatment, or who have had allogenic hematopoietic stem cell transplantation before relapse |
Country | Name | City | State |
---|---|---|---|
France | University Hospital of Amiens | Amiens | |
France | University Hospital of Angers | Angers | |
France | University Hospital of Besancon | Besançon | |
France | University Hospital of Bordeaux | Bordeaux | |
France | University Hospital of Caen | Caen | |
France | Civil Hospices of Lyon | Lyon | |
France | University Hospital of Marseille | Marseille | |
France | University Hospital of Nancy | Nancy | |
France | University Hospital of Nantes | Nantes | |
France | University Hospital of Nice | Nice | |
France | University Hospital of Robert Debre (Paris) | Paris | |
France | University Hospital of Trousseau (Paris) | Paris | |
France | University Hospital of Reims | Reims | |
France | University Hospital of Rennes | Rennes | |
France | University Hospital of Saint Etienne | Saint-Étienne | |
France | University Hospital of Strasbourg | Strasbourg | |
France | University Hospital of Toulouse | Toulouse | |
France | University Hospital of Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measure of Treg (CD4+,CD25+, Foxp3+) and deficient natural killer (NK) cells (CD3-,CD56+,NKp30-) proportions by FACS in children newly diagnosed with their first relapse of B-ALL. | Comparison of the immune status of patients at the diagnosis of their first relapse diagnosis with those of children treated for B-ALL who are in complete remission and at the same stage of treatment. | At the time of the inclusion. | |
Secondary | Measure of the number of T CD4+ lymphocytes (Cluster of Differentiation 4), T CD8+ lymphocytes (Cluster of Differentiation 8), NK cells and Natural killer T (NKT) cells by FACS. | At the time of the inclusion. | ||
Secondary | Measure of percentage of TCD4+ naive and memory cells and TCD8+ naive and memory cells by FACS. | At the time of the inclusion. | ||
Secondary | Measure of percentage of gamma delta and alpha-bêta TCR CD3+ T cells by FACS. | At the time of the inclusion. | ||
Secondary | Measure of TRECs (T cell receptor excision circle) by QPCR and naïve CD4+CD45RA+CD31+ T cells by FACS. | At the time of the inclusion. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05557110 -
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
|
Phase 2 | |
Recruiting |
NCT04872790 -
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT02458014 -
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
|
Phase 2 | |
Active, not recruiting |
NCT03233854 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT03959085 -
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
|
Phase 3 | |
Recruiting |
NCT03856216 -
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT03241940 -
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02484430 -
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT02146924 -
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT02877303 -
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT03488225 -
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT02968472 -
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
|
Phase 1 | |
Recruiting |
NCT05157971 -
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT05310591 -
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02143414 -
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Completed |
NCT03289455 -
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
|
Phase 1/Phase 2 | |
Suspended |
NCT03150693 -
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
|
Phase 3 | |
Not yet recruiting |
NCT06317662 -
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
|
Phase 2 | |
Recruiting |
NCT03914625 -
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
|
Phase 3 | |
Not yet recruiting |
NCT06124157 -
A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)
|
Phase 3 |